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Abstract
Targeting the tumor vasculature and selectively modifying endothelial functions is an attractive anti-tumor strategy. We prepared
polyethyleneglycol modified immunoliposomes (IL) directed against vascular cell adhesion molecule 1 (VCAM-1), a surface receptor over-
expressed on tumor vessels, and investigated the liposomal targetability in vitro and in vivo. In vitro, anti-VCAM-1 liposomes displayed specific
binding to activated endothelial cells under static conditions, as well as under simulated blood flow conditions. The in vivo targeting of IL was
analysed in mice bearing human Colo 677 tumor xenografts 30 min and 24 h post i.v. injection. Whereas biodistribution studies using [3H]-labelled
liposomes displayed only marginal higher tumor accumulation of VCAM-1 targeted versus unspecific ILs, fluorescence microscopy evaluation
revealed that their localisations within tumors differed strongly. VCAM-1 targeted ILs accumulated in tumor vessels with increasing intensities from
30 min to 24 h, while control ILs accumulated in the tumor tissue by passive diffusion. ILs that accumulated in non-affected organs, mainly liver and
spleen, primarily co-localised with macrophages. This is the first morphological evidence for selective in vivo targeting of tumor vessels using ILs.
VCAM-directed ILs are candidate drug delivery systems for therapeutic anti-cancer approaches designed to alter endothelial function.
© 2007 Elsevier B.V. All rights reserved.Keywords: Immunoliposome; Tumor; Vascular targeting; VCAM-1; Tumor xenograft model1. Introduction
Specific delivery of therapeutic agents incorporated into
nanoparticles, such as liposomes, to endothelial cells is an
attractive strategy for modifying vascular function in various
pathological states, e.g. cancer and inflammation. Accordingly,
there is an increasing interest in approaches that target the tumor
vasculature during growth, development and metastasis and aim
at either destroying existing tumor vessels, specifically occlud-
ing tumor vasculature or at interfering with the process of
angiogenesis [1–3]. Vascular targeting agents bypass the need
for extravasation from the bloodstream, as endothelial cells are
directly accessible to i.v. administered drugs. Targeting the
vasculature offers several additional advantages: 1) an ampli-⁎ Corresponding author. Tel.: +4550472893; fax: +49 228737929.
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doi:10.1016/j.bbamem.2007.12.021fication effect, as each tumor vessel feeds a large number of
tumor cells; 2) a reduced risk of acquired drug resistance be-
cause endothelial cells are genetically more stable than tumor
cells [4]; 3) a broad application spectrum since tumor endo-
thelial cell markers are shared by many different tumor types [5]
and since the dependence of tumor growth on neovascularisa-
tion [6] is not tumor type specific.
Liposomes are biocompatible nanoscale drug carriers sys-
tems. Their sterical stabilisation by, e.g. incorporation of poly-
ethyleneglycol (PEG) lipids into the bilayer mediates long
circulation half-lives of about 16 h in mice or rats, and 24 h or
longer in humans after i.v. administration [7]. The coupling of
antibodies onto the surface of PEGylated liposomes results in
immunoliposomes (ILs) and allows for specific targeting [8].
ILs have been studied extensively with respect to the antibody
coupling procedure [9], sterical stabilization [10] and immuno-
genicity [11,12]. Several in vitro studies reported targeting of
ILs to endothelial cells with the future goal to localise liposomes
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receptors in those studies included endoglin [13], vascular en-
dothelial growth factor receptor 2 [14], intercellular adhesion
molecule 1 [15], E-selectin [16,17] and vascular cell adhesion
molecule 1 (VCAM-1) [18–20]. In vivo, ILs have been demon-
strated to target to inflamed vasculature [21] or vessels in the
area of myocardial infarction [22].
Several in vivo studies have investigated the vascular tar-
getability of liposomes decorated with peptides. These peptides
include RGD motifs binding to αvβ3 integrins [reviewed in
[23], NGR motifs binding to aminopeptidase N [24], CREKA
binding to fibrinogen or fibrin [25], or GPLPLR binding to
membrane type-1 matrix metalloproteinase [26]. While the
generally lower binding affinity of peptides compared to anti-
bodies can be of advantage for targeting the tumor cell com-
partment [27] high affinity binding appears to be preferable for
robust tumor vascular targeting, since ligands binding to the
luminal side of blood vessels are exposed to the dynamic flow
environment of the bloodstream. Multivalent avidity effects can
drastically increase overall binding of particles coated with low
affinity ligands; yet Zhou et al. reported that below a certain
ligand density the affinity of the monovalent ligand influences
the binding properties of the multivalent particle [28].
In order to generate carriers with sufficient binding affinity
and selectivity, the experimental design introduced here incor-
porates the use of an anti-VCAM antibody as a homing device.
VCAM-1 is an immunoglobulin-like transmembrane glycopro-
tein expressed on activated endothelial cells during inflamma-
tion and cancer [29]. VCAM-1 promotes firm cell–cell
adhesion. One of its ligands is the integrin VLA-4 which is
expressed on inflammatory leukocytes, on some tumor cells and
also on tumor endothelial cells. The VCAM–VLA4 interaction
promotes cell–cell contact between leukocytes and inflamed
endothelium [30], VCAM-positive pericytes and tumor endo-
thelium [31], proangiogenic macrophages and tumor endothe-
lium [32], and metastatic tumor cells and tumor vasculature [33]
and thus plays a role in tumor angiogenesis and metastasis.
VCAM-1 expression is inducible and virtually absent on normal
human vasculature [34]. Non-vascular cells with VCAM-1 ex-
pression include bone marrow cells, follicular dendritic cells,
fibroblasts, and epithelial cells in the kidney [35,36]. Several
diseases are associated with VCAM-1 expression on the vas-
cular endothelium, such as atherosclerosis, inflammatory di-
seases and autoimmune diseases [37]. In cancer, the robust
vascular VCAM-1 expression has been observed in leukemias
and lymphomas, such as Hodgkin's disease and B-CLL, and to
varying extents also in a variety of solid tumors such as lung
cancer, breast cancer, melanoma, renal cell carcinoma, gastric
cancer and nephroblastoma [reviewed in [38]]. Upon ligand
binding, VCAM-1 is internalised via a clathrin dependent path-
way with a half life of 15 min [39].
The biodistribution of sterically stabilized liposomes after
systemic administration has been studied extensively [reviewed
in [7]]. Although a dominant fraction of liposomes is taken up
by organs attributed to elimination through the reticuloendothe-
lial system (RES), especially liver and spleen, the long systemic
circulation time of PEGylated liposomes permits accumulationof liposomes in non-RES sites, such as inflammatory or tumor
tissues [40,41].
In this study, we investigated whether PEGylated immuno-
liposomes directed against a tumor vascular surface receptor
would selectively bind activated endothelial cells in vitro and
home to tumors in vivo. In addition, the cellular in vivo dis-
tribution of VCAM-targeted ILs within target and non-target
tissues was assessed. To our knowledge this is the first report to
demonstrate morphological evidence of IL targeting to tumor
vasculature in vivo. Our findings suggest VCAM-directed ILs
as promising carriers for anti-tumor therapeutics at the endo-
thelial level.
2. Materials and methods
2.1. Reagents
Reagents were obtained from the following sources: soy phosphatidyl
choline (SPC) was kindly donated by Lipoid AG Ludwigshafen (Germany),
polyethylenglycol-phosphatidylethanolamine (PEG-PE) was purchased
from Avanti Polar Lipids (Alabaster, USA). Cyanuric chloride, cholesterol (Chol),
1-ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC),N,N-diisopropylethylamine,
3,3′-Dioctadecyloxacarbocyanine perchlorate (DiO) and recombinant murine tumor
necrosis factor-α (TNF-α), Folin–Ciocalteus phenol were from Sigma-Aldrich
(Deisenhofen, Germany). The membrane anchor, cyanur-PEG-PE, for antibody
coupling was synthesized by our group as previously described [42]. Antibodies used
in this studywere as follows: rat anti-mouseVCAM-1 (cloneMK271), rat anti-mouse
CD31 (clone 390) and rat anti-mouse Meca32 antigen (clone Meca32) were purified
from hybridoma cell supernatant (see Section 2.2) using rat anti-mouse-IgG-agarose
affinity columns (resin from Sigma-Aldrich); isotype-matched rat control antibodies
(IgG1) and anti-CD11b (clone OX 42) were obtained from BD Pharmingen
(Heidelberg, Germany); fractionated human IgGwith irrelevant specificity and FITC-
conjugated goat anti-rat secondary antibody from Sigma-Aldrich; anti-macrophage
BM8 antibody, recognizing the F4/80 maturation antigen, from Dianova (Hannover,
Germany); and Alexa Fluor® 568 conjugated goat anti-rat secondary antibody from
Molecular Probes (Invitrogen, Karlsruhe, Germany).
2.2. Cell lines
Hybridoma cell line MK271 was from ATCC, Manassas, VA, USA; hybri-
doma cell line 390 was from S. Albelda, University of Pennsylvania, Phila-
delphia, PA, USA; hybridoma cell line Meca32 was from E. Butcher, Stanford
University, Stanford, CA, USA. Murine brain endothelioma cells bEnd.3 were
obtained from B. Engelhardt, Theodor Kocher Institute, University of Bern,
Switzerland. A2780 is a human ovarian cancer cell line obtained fromM.Wiese,
Pharmac. Dept., University Bonn. Human tumor cell line Colo677, originally
described as non-small cell lung cancer cell line, is a myeloma cell line from
DSMZ, Braunschweig, Germany, which forms solid tumors with VCAM-
positive vessels after subcutaneous injection [38]. All cell lines except bEnd.3
were cultured in RPMI 1640 medium supplemented with 10% foetal calf serum
(FCS), 100 U penicillin and 100 μg streptomycin at 37 °C in a 5% CO2
incubator. The bEnd.3 cells were grown in Dulbecco's modified Eagle's med-
ium (DMEM) supplemented with 10% FCS, 100 U penicillin, 100 μg strep-
tomycin and 4 mM glutamine. All cell culture reagents were obtained from
Sigma-Aldrich.
2.3. Liposome preparation and characterisation
Liposomes were prepared from soyPC/Cholesterol/cyanur-PEG2000-PE/DiO
in a ratio of 64.5/30/5/0.5 mol%. In some preparations, trace amounts of [3H]-
cholesteryloleylether (Amersham, Buckinghamshire, U.K.) (0.25 μCi/μmol
lipid) or 0.1 mol% rhodamine-DSPE (Avanti Polar lipids, Alabaster, USA) was
added instead of the DiO label. Lipid films were hydrated with a 0.9% NaCl
solution to reach a final lipid concentration of 30 mM. Unilamellar liposomes
were prepared with a Mini-extruder, (Avanti Polar Lipids, Alabaster, USA),
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membrane, 19 times through a 100 nm polycarbonate membrane and 10 times
through a 50 nm polycarbonate membrane (Whatman Nuclepore 18 mm
polycarbonate membrane, Richmond, USA). To couple a protein to the lipo-
somal surface, the cyanur-PEG2000-PE anchor was used, which couples the
targeting devices to the terminal ends of the PEG chain [42]. An anti-VCAM
monoclonal antibody (mAb) (M/K-271) was used as a homing device. Control
liposomes were coupled to an irrelevant IgG (human fractionated IgG with
∼70% IgG1 content or purified rat IgG1) or to bovine serum albumin (BSA)
(grade V). Coupling was performed in a 1:1000 protein:lipid molar ratio. The
cyanur ILs were prepared as previously described [12]. Briefly, the calculated
amount of antibody was added to liposomes in borate buffer (pH=8.8) and
incubated at room temperature for about 16 h. Unbound antibodies were separ-
ated by gel permeation chromatography using a Sepharose 4B column.
Liposomes were characterised with respect to particle size by dynamic light
scattering (Malvern autosizer IIc, Malvern, UK), and with regards to phospho-
lipid concentration [43]. The concentration of coupled proteins was determined
with a modified Lowry assay [44]. Briefly, the proteins were first precipitated
with 0.3% Na-deoxycholate and 70% trichloric acid and centrifuged for 20 min
at 11,000 rpm at 4 °C. Thereafter, 1 ml of buffered CuS04 solution C was added
(2 mM CuSO4 ⁎ 5H2O, 3.3 mM Na3C6H5O7 ⁎ 2H2O, 3.8 mM Na2C03, 2 mM
NaOH), vortexed, and incubated at room temperature for 10 min. 50 μl Folin–
Ciocalteus phenol was added and the samples were vortexed and incubated for
30 min at room temperature in the dark. Absorbance was read at A750. A
calibration curve was performed using either human IgG or BSA as reference for
the respective liposomes.
2.4. Fluorescence associated cell sorting (FACS) analysis
VCAM-1 expression on activated bEnd.3 cells was analysed by FACS.
bEnd.3 cells were incubated with 50 ng/ml TNF-α for 4 h, detached with
0.025% EDTA, rinsed twice in washing buffer (PBS containing 1% BSA) and
fixed in 4% neutral buffered paraformaldehyde for 10 min at room temperature.
After two more washes, cells were stained with rat anti-mouse VCAM mAb
MK271 (10 μg/ml) for 1 h on ice and labelled with FITC-conjugated goat anti-
rat secondary antibody for 30 min on ice, prior to analysis on a flow cytometer
(BD Biosciences, San Jose, CA, USA).
Liposomal binding to the b.End3 cells was determined by FACS analysis.
bEnd.3 cells were seeded in 96-well microtiter plates (density: 1×105 cells/well)
24 h prior to the assay. The cells were activated with TNF-α (50 ng/ml) for 4 h to
ensure VCAM expression. Four different liposome preparations carrying a DiO
label, were investigated: anti-VCAM mAb-liposomes (α-VCAM-L), liposomes
conjugated to rat IgG1 (rIgG-L) or human IgG (hIgG-L) of irrelevant specificity
and albumin-liposomes (Alb-L). The liposomes (75 nmol) were incubated with
the cells for 1 h at 4 °C in normal cell medium. Unbound liposomes were
removed by washing with PBS. The cells were detached with 0.025% EDTA
and liposomal binding was analysed on the flow cytometer.
2.5. Fluorescence based cell assay
Binding of VCAM-directed liposomes to murine endothelial cells was also
measured using a fluorescence based cell assay in comparison to control lipo-
somes. Murine endothelial cells bEnd.3 were seeded and activated with TNF-α
as described in Section 2.4.
Four different liposome preparations (see Section 2.4) carrying a DiO label,
were investigated. The liposomes (75 nmol) were incubated with the cells for 1 h
at 4 °C in normal cell medium. Unbound liposomes were removed by washing
with PBS containing 1 mMCaCl2 and 0.5 mMMgCl2 and the liposomal binding
was analysed in a FLUOstar Optima microplate reader (BMG Labtech, Offen-
burg, Germany).
To measure internalisation of VCAM-directed liposomes upon binding to
bEnd.3 endothelial cells, the same procedurewas followed as described above except
that the cells were incubated with liposomes for 2 h at 37 °C. Thereafter, unbound
liposomeswere removed bywashingwith PBS containing 1mMCaCl2 and 0.5mM
MgCl2 and liposome binding was measured. To determine the fraction of cell-
associated liposomes that were internalised, the cells were stripped of their surface-
bound liposomes by one wash with citrate buffer (pH=3.0) followed by one wash
with PBS. The remaining cell-associated liposomes were considered internalised.2.6. Dynamic flow assay
In order to simulate the in vivo binding of the liposomes to the endothelial
cells under shear force conditions, a dynamic flow assay was performed as
previously described [17]. Briefly, the endothelial cells were seeded on circular
(18 mm) coverslips (5×105 cells) 24 h prior to the assay. The cells were activated
with TNF-α (50 ng/ml) for 4 h and subsequently washed once with PBS. The
coverslips were inserted into a doublet flow chamber. Each chamber was
perfused with 5 ml of RPMI 1640 medium containing 1% penicillin/
streptomycin, 10% FCS and 0.5 μmol liposome dispersion for 20 h at a shear
rate mimicking capillary blood flow (about 200 s−1) using a peristaltic pump at a
temperature of approx. 37 °C. Two different liposome preparations, carrying a
rhodamine label, were investigated; α-VCAM-L and hIgG-L. At different time
points (t=0, 1 h, 2 h and 20 h), the flowwas stopped and pictures of the liposomal
binding to the cell layer were taken through an inverted fluorescence microscope
Axiovert 200 equipped with a AxioCam MRc camera (Carl Zeiss, Germany).
2.7. Xenograft mouse model and biodistribution studies
FemaleCD1 nudemice (Charles River Laboratories, Germany)were housed in
cages with free access to food and water with a 12 h light/dark cycle. Human Colo
677 xenograft tumors were created by a subcutaneous co-injection of 1×107 Colo
677 cells with Matrigel (BD Science, Heidelberg, Germany) diluted 1:1 into one
flank of 4–5week-oldmice. The tumor size wasmeasured every second daywith a
calliper in three perpendicular directions a, b and c, and tumor volumes were
calculated according to the formula V=π/6×a×b×c. When the tumors had grown
to 200–500mm3, themicewere injectedwith 0.5 μmol liposomes into the tail vein.
Three different liposome preparations were investigated; α-VCAM-Ls, irrelevant
IgG-liposomes and albumin-liposomes (n=3 per group), all containing DiO as a
fluorescent label. The mice were sacrificed either 30 min or 24 h after liposome
injection. Experiments were terminated by transcardial perfusion of deeply
anesthetised mice with PBS for 10 min and major organs and tumors were snap
frozen in dry ice/isopentane slush and stored at−80 °Cuntil further use. The organs
and tumors were cut into 5 μm sections on a Leica CM 3050 G cryostat (Leica,
Wetzlar, Germany) and were either used directly or stored at −80 °C.
Total liposome tumor accumulation and biodistribution was investigated
using Tritium-labelled liposomes. [3H]-labelled liposomes coupled to either
anti-VCAM antibody or an irrelevant human IgG were injected i.v. at a dose of
0.5 μmol liposome/mouse (n=4–5 mice per group). The animals were anes-
thetised after 24 h and blood was collected by heart puncture. This was followed
by a transcardial perfusion with PBS for 10 min before liver, spleen, kid-
ney, lungs, heart, skin, muscle and tumor were removed, weighed and stored at
−20 °C until further use. To measure the amount of accumulated radioactive
liposomes in the organs and tumor, the tissues were homogenised using a Potter
Elvehjelm tube in 3 ml homogenisation buffer (50 mM Tris–HCl; 100 mM
NaCl, 1 mM EGTA, 10 mM MgCl2, 1% Triton X-100) per gram of tissue.
Radioactivity was measured in 500 µl tissue homogenate after adding 100 μl of
10% SDS and 4 ml scintillation liquid (Ultima Gold). Blood samples were
allowed to clot for 3 h and centrifuged for 20 min at 13,520 ×g at 4 °C [12].
2.8. Fluorescence microscopy of tissue sections
Cryosections of tumors and organs from the mouse tumor model were
thawed, fixed in 4% paraformaldehyde for 10 min and incubated with one of the
following primary antibodies: rat anti-mouse CD31 or rat anti-mouse Meca32
against endothelial cells; rat anti-mouse BM8 against macrophages; and rat anti-
mouse CD11b against macrophages and dendritic cells. Sections were incubated
with primary antibodies for 1 h at room temperature. Excess primary antibody
was removed by three successive washes for 5 min with PBS. Thereafter, Alexa
Fluor 568 conjugated secondary antibody was applied for 1 h at room tem-
perature, followed by three washes with PBS. Coverslips were mounted with a
fluorescence-mounting medium (Dako, Glostrup, Denmark). The sections were
stored in the dark at 4 °C until further analysis. Overlay analysis was performed
using AxioVision software (Carl Zeiss AxioVision release 4.6). Percentages of
liposomes co-localised with the endothelium were determined in four ran-
domised microscopic fields and calculated as the ratio between the amount of
co-localised pixels×100 and the number of total green pixels. The co-
localisation percentages are given as mean±SD.
Fig. 1. The in vitro targeting of liposomes to VCAM-1 expressing bEnd.3 cells
A: FACS analysis of the increased VCAM-1 expression of bEnd.3 cells after
activation with TNF-α (50 ng/ml) for 4 h. The grey peak illustrates the non-activated
cells; the black line illustrates theTNF-α activated cells. B:Comparison of the binding
efficiency of anti-VCAM directed ILs (α-VCAM-L), ILs with coupled rat IgG1
(rIgG-L) or human IgG (hIgG-L) of irrelevant specificity and albumin (Alb-L) to
bEnd.3 cells using the fluorescence based cell assay, ⁎⁎pb0.005 α-VCAM-L
versus all three control liposome populations. C: Comparison of the targetability of
α-VCAM-L, rIgG-L, hIgG-L and Alb-L to activated bEnd.3 cells analysed by
FACS. ⁎⁎⁎p=0.001 α-VCAM-L versus all control liposomes. Data points
represent the average of at least three experiments, error bars are SD.
Table 1
Comparison of the liposomal characteristics with respect to particle size and
protein coupling yield
Particle size(nm) Polydispersity μg protein/
μmol PL
Protein content:
molecule per
liposome
α-VCAM-L 83.1±14.4 0.13±0.05 59.0±17.9 52.3±15.8
rIgG-L 93.4±12.0 0.15±0.04 67.0±51.8 68.2±36.1
hIgG-L 91.3±13.2 0.12±0.06 74.4±40.2 71.1±35.2
Alb-L 84.5±13.1 0.15±0.06 70.3±42.0 85.0±4.31
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Statistical significance between groups in the in vitro binding assays and in
the in vivo biodistribution experiment was calculated using unpaired Student's
t-test. Significance was assumed at a p-valueb0.05.
3. Results and discussion
3.1. Targeting of VCAM-directed ILs to bEnd.3 cells in vitro
The murine endothelial cell line bEnd.3 was chosen for the
establishment of an in vitro model of vascular liposomal tar-
geting. Flow cytometry was used to ensure that these cellsindeed expressed VCAM-1 on their surface. Although the non-
activated bEnd.3 cells also exhibited some surface expression of
VCAM, 4 h incubation with TNF-α increased VCAM expres-
sion, as illustrated in Fig. 1A. Based on these data, all further
experiments were carried out with bEnd.3 cells activated for 4 h
with TNF-α.
Fluorescence-labelled liposomes were prepared with differ-
ent proteins coupled to the PEG terminus via cyanur-PEG2000-
PE anchor. Liposomes carrying anti-VCAMmAb (α-VCAM-L)
were compared to liposomes carrying a rat IgG1 (rIgG-L) or
a human IgG of irrelevant specificity (hIgG-L) and albumin-
conjugated liposomes (Alb-L). The liposomes were charac-
terised with respect to particle size and coupling efficiency, as
illustrated in Table 1.
The liposome populations were comparable in size and
protein coupling, therefore, any differences in targeting beha-
viour should not be related to their physical characteristics.
Furthermore, protein coupling did not significantly influence
the liposomal size distribution. Size characteristics were cons-
tant and remained unchanged throughout the experiments.
The targetability of the four different liposomal preparations
to activated bEnd.3 cells was initially analysed in a fluorescence
microplate assay. α-VCAM-L bound with significantly higher
intensity (pb0.005) to the activated endothelial cells than con-
trol liposomes, as illustrated in Fig. 1B. There were no dif-
ferences between binding of the purified rat IgG1-conjugated
liposomes (rIgG-L) and the fractionated human IgG-conjugated
liposomes (hIgG-L) to the target cells. Furthermore, no binding
to a VCAM-negative control cell line (A2780, data not shown)
was observed.
Binding was also analysed by flow cytometry, since the
interrogation of single cells in solution represents more accurate
data and generally gives better signal to background ratios by
eliminating background fluorescence remaining in the well after
washes. Indeed, the VCAM-mediated binding of α-VCAM-L
was not only confirmed but showed a higher difference in
comparison with negative controls (Fig. 1 C; pb0.001). Static
binding of liposomes to the cell surface does not mimic the
vascular targeting of liposomes under physiological shear force
conditions in circulation, especially considering the highly
variable flow conditions in tumor vasculature [45]. Therefore,
we employed a flow chamber assay [17] to investigate whether
liposome binding was sufficient to target bEnd.3 cells under
shear force conditions similar to those found in capillary venu-
les. Binding of α-VCAM-L and hIgG-L to endothelial cells was
followed microscopically over a time period of 20 h. As shown
Fig. 2. Binding of rhodamine-labelled α-VCAM-L to stimulated bEnd.3 cells under shear force conditions, illustrated as a phase contrast image (left), as fluorescence
image (middle) and as an overlay image (right). The binding of rhodamine-labelled α-VCAM-L onto the cell monolayer was analysed at 0, 1 and 20 h (A–C) and
compared to the binding of rhodamine-labelled hIgG-L after 20 h (D). The bar represents 50 μm.
Fig. 3. Comparisonof the quantitative tumor accumulationofα-VCAM-LandhIgG-L.
The [3H]-activity in tumors was detected 30 min and 24 h after injection of the [3H]-
labelled liposomes into Colo 677 tumor xenograft mice (data are mean±SD, n≥4).
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increased in a sustainable manner illustrated by the increasing
fluorescence intensity with time. In contrast, no binding was
observed with the hIgG-L (Fig. 2 D).
It has previously been shown that VCAM-targeted liposomes
were internalised upon binding [19]. We investigated the endo-
cytosis of VCAM-targeted liposomes and found that approxi-
mately 8% of the bound α-VCAM-L were internalised by the
activated endothelial cells after 2 h at 37 °C; therefore the
staining of the bEnd.3 cells (Fig. 2 C) represents both inter-
nalised and surface-bound liposomes.
3.2. Targeting of α-VCAM-liposomes to tumor endothelial cells
in vivo
Since the in vitro results appeared promising, the vascular
targeting of α-VCAM-L was investigated in mice bearinghuman Colo 677 xenograft tumors. In this model solid tumors
are formed upon subcutaneous injection of tumor cells and
∼30% of the tumor vasculature is VCAM-positive [38]. The
Fig. 4. Localisation of the different liposome populations within the tumors. (A1–6)α-VCAM-L 30min after i.v. injection; (B1–6)α-VCAM-L 24 h after i.v. injection; (C1–6)
hIgG-L 24 h after i.v. injection; (D1–6)Alb-L, 24 h after i.v. injection illustrating high degree of co-localisation for A andB, but not for C andD. 1) liposome distribution (green);
2) endothelial staining with CD31 (red); 3) overlay at low magnification; 4) liposome distribution (green); 5) endothelial staining with CD31 (red); and 6) overlay at high
magnification of liposome distribution (green) and endothelial marker CD31 (red). The bar in the low magnification images corresponds to 50 μm. The bar in the high
magnification images corresponds to 5 μm.
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Table 2
Biodistribution of α-VCAM-L and hIgG-L after 24 h as % injected dose per
gram tissue
Muscle Skin Heart Lung Kidney Spleen Liver Blood
α-VCAM-L
24 h
0.25±
0.18
0.69±
0.45
1.03±
0.67
1.85±
0.94
3.59±
2.14
3.40±
2.32
8.11±
1.24
1.02±
0.82
hIgG-L
24 h
0.46±
0.14
0.99±
0.53
0.97±
0.37
1.66±
0.13
2.65±
1.73
3.3±
0.26
6.72±
2.20
1.11±
0.39
Statistics
(p=) 24 h
0.131 0.42 0.893 0.747 0.546 0.945 0.286 0.864
860 S. Gosk et al. / Biochimica et Biophysica Acta 1778 (2008) 854–863model was chosen because in mice, VCAM expression on
tumor blood vessels in other tumor models is generally low, in
contrast to tumor vascular VCAM expression in humans [38].
First, the tumor accumulation of α-VCAM-L versus hIgG-L,
30 min and 24 h after i.v. injection was quantified detecting the
[3H]-labelled liposomes in the tumor tissue. The data given in
Fig. 3 indicates that the accumulation of both liposomal popu-
lations increased with time. At 24 h, about 2% of the injected
dose per gram of tissue were localised to the tumor, although –
in contrast to human tumors – only ∼30% of tumor vessels
show a medium strong expression of VCAM-1 in this mouse
model [38].
The tumor accumulation of VCAM-directed ILs was slightly
higher than that of control liposomes, but this difference did not
reach statistical significance. This was not unexpected and should
be related to unspecific tumor accumulation of the control lipo-
somes. Unspecific accumulation of liposomes has been described
previously [40,41,46] and is attributed to an enhanced perme-
ability and retention effect [47]. However, differences between
unspecific and specific tumor targeting of liposomes can not be
distinguished by this quantitative evaluation.
In order to evaluate whether vascular-directed versus un-
specific ILs were localised to different compartments within the
tumor, we investigated the targeting behaviour of DiO-labelled
ILs by fluorescence microscopy. The images, given in Fig. 4
clearly indicate that tumor accumulation of α-VCAM-L already
was evident after 30 min (Fig. 4 A1) and had further increased
by 24 h (Fig. 4 B1). At both time points the tumor accumulation
of α-VCAM-L was more intense than that of both control
liposomes (Fig. 4 C1–D1), which was not expected according
to the data in Fig. 3. The lower fluorescence intensity of the
control liposomes in the tumors could be related to a higher
degree of extravasation and dilution of the liposomes through-
out the tumor, so that their fluorescence is below the detection
level.
To confirm whether the different liposomes were localised to
tumor vasculature, tumor sections were counterstained with a
fluorescent antibody against murine CD31 (Fig. 4 A2–D2).
This double labelling procedure (Fig. 4 A3 and B3 low mag-
nification, A6 and B6 high magnification) revealed a clear co-
localisation between the α-VCAM-L and the endothelium after
30 min (91.7%) and after 24 h (73.1%). On the contrary, both
types of control liposomes displayed a much lower degree of
co-localisation with vascular endothelium (30.3% and 23.7%,
resp.; Fig. 4 C3–D3 low magnification, C6–D6 high magni-
fication). Endothelial cells are known to express receptors both
for the Fc portion of antibodies [48] and for albumin [49].
Labelling of activated endothelial cells with a negative control
IgG-antibody coupled to nanoparticles has been described in a
mouse model for vascular inflammation [50]. This background
binding could probably be decreased if recombinant antibody
fragments devoid of the Fc portion, such as single chain variable
fragments, were to be used as a targeting moiety.
Our data indicate that the α-VCAM-L behaves differently
from the unspecific tumor accumulation of non-targeted lipo-
somes arguing for a specific and receptor-mediated vascular
targeting. Similar to this study, Kirpotin et al. recently investigatedthe distribution and localisation of liposomes targeted against
tumor cells as compared to non-targeted liposomes. Their results
showed that although approximately the same amounts of lipo-
somes were found in the tumor, the specific localisation of the
liposomes differed. The non-targeted liposomes accumulated in
the perivascular and extracellular space, whereas the targeted
liposomes were found in the tumor cell cytosol [51]. Knowledge
about the cellular distributionwithin the tumor is important for the
choice of an appropriate effector molecule.
3.3. The localisation of liposomes in organs
To investigate whether α-VCAM-L would target vasculature
outside the tumor, the localisation of the liposomes in major
organs, such as heart, lung, liver, spleen and kidney, was in-
vestigated. The biodistribution of the liposomes was quantita-
tively determined using [3H]-labelled α-VCAM-L and hIgG-L
with subsequent activity detection in the organs after 24 h. The
data given in Table 2 indicate that the majority of liposomes was
detected in the liver (8% ID/g), followed by kidney, spleen, and
lung, whereas other organs showed lower liposome accumula-
tion. A high uptake into liver, spleen and lung was not unex-
pected, since localisation of liposomes into these organs is a
well known phenomenon and is generally attributed to extrac-
tion via the RES [41]. No statistically significant differences
were seen between VCAM-targeted liposomes and control
liposomes, consistent with unspecific accumulation as part of
the liposome elimination pathway. This is different from prev-
ious reports with both NGR-targeted and RGD-targeted lipo-
somes, which accumulate in higher amounts in the lung and/or
spleen [52,53].
To define the tissue compartments to which the liposomes
localised, a similar study as described above was carried out.
Cryostatic sections of lungs, kidneys, liver and spleen from
mice injected with DiO-labelled liposomes (Fig. 5 A–D, left
images) were counterstained with fluorescent antibodies detec-
ting either endothelial cells (Fig. 5 A–D, middle) or tissue
resident macrophages (Fig. 5 A–D, right). Liposome signals in
the lung were rare and, if present, co-localised primarily with
alveolar macrophages (Fig. 5 A, right). Fluorescent signals in
the kidney were observed in glomeruli, occasionally on endo-
thelial cells, in tubuli and as scattered events. Glomerular stain
could be explained by VCAM expression of mesangial cells
[36]. In contrast to human kidneys [34], endothelial cells in
murine kidneys show a low level of VCAM expression [54] and
Fig. 5. Distribution of liposomes in lung, kidney, liver and spleen from tumor bearing mice 24 h after i.v. injection. A: Lung section showing the α-VCAM-L
distribution (left); lung section double-stained against the endothelial marker Meca32 (middle); and double-stained against the macrophage marker CD11b (right).
Note that the liposomes in the lung are co-localised with the lung macrophages. B: Kidney section showing the distribution of α-VCAM-L (left); kidney section
double-stained against the endothelial marker CD31 (middle); and kidney section double-stained against the macrophage marker CD11b (right). C: Liver section
illustrating the α-VCAM-L (green) distribution (left); liver section double-stained against the endothelial marker Meca32 (middle); and liver section double-stained
against the macrophage marker F4/80 (right). Note the clear co-localisation between the liver macrophages and liposomes. D: Spleen section showing the distribution
of VCAM-L (green) in the white pulp and marginal zone (left); spleen section double-stained against the endothelial marker Meca32 (middle); and spleen section
double-stained against the macrophage and dendritic cell marker CD11b (right). The bar in the low magnification images corresponds to 50 μm. The bar in the high
magnification images corresponds to 5 μm.
861S. Gosk et al. / Biochimica et Biophysica Acta 1778 (2008) 854–863Gottstein C., unpublished data]. The tubular stain appeared more
diffuse and might be due to free dye reabsorbed by the tubuli
after escaping into the glomerular filtrate. Scattered staining was
found within tubular lumina, and also in co-localisation with
kidney macrophages (Fig. 5 B, right).
The liver sections exhibited a clear co-localisation between
the liposomes and liver macrophages (Fig. 5 C, right image),
while virtually no co-localisation was observed in sections
stained against the endothelium (Fig. 5 C, middle).
In the spleen, liposome signals were prominent in the mar-
ginal zone, in accordance with previous studies [55,56]. No co-
localisation with spleen vasculature was observed (Fig. 5 D,middle). Instead, we found co-localisation with F4/80 positive
macrophages in the red pulp (not shown) and with CD11b
positive cells (Fig. 5 D, right). CD11b is a marker for macro-
phages and also for dendritic cells, which are known to express
VCAM-1.
In summary, these results provide evidence, for the first time,
that immunoliposomes can be effectively targeted to tumor
vasculature in vivo. No significant vascular binding was ob-
served to any of the organs investigated, although further
studies are needed to evaluate localisation in a broader set
of normal tissues. This recommends VCAM-1 targeted ILs as
candidate drug carriers for tumor vascular delivery.
862 S. Gosk et al. / Biochimica et Biophysica Acta 1778 (2008) 854–863While VCAM-1 expression on vasculature is for the most
part restricted to pathological conditions, several non-vascular
cells also express VCAM-1 [35,36]. This is of minor concern as
long as effectors are chosen, that are designed to alter vascular
specific functions. Examples include angiogenesis inhibitors,
sensitizers for specific vascular occlusion-inducing agents [57]
and intracellularly acting modifiers of angiogenesis associated
signal transduction pathways [58].
4. Conclusions
The tumor vasculature has been recognized as an attractive
drug target, and the means for efficient delivery of payloads to
tumor vascular markers are in demand. We have generated long
circulating immunoliposomes (ILs) targeted to VCAM-1. This
study provides the evidence that 1) α-VCAM-Ls specifically
bound to activated endothelial cells in vitro under static and
flow conditions; 2) α-VCAM-Ls, but not control liposomes,
effectively targeted tumor endothelial cells in vivo; 3) localisa-
tion of VCAM-targeted ILs in non-target organs was primarily
found in phagocytic cells and not co-localised to the vasculature
and 4) RES uptake of the targeted ILs is not significantly higher
compared to non-targeted ILs.
In summary, PEGylated α-VCAM-Ls are candidate drug
carriers for delivery of vascular specific payloads to tumor
vasculature and further studies are warranted to evaluate their
suitability for clinical applications.
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